Tvardi Therapeutics (TVRD) Income from Continuing Operations: 2013-2017
Historic Income from Continuing Operations for Tvardi Therapeutics (TVRD) over the last 5 years, with Sep 2017 value amounting to -$12.4 million.
- Tvardi Therapeutics' Income from Continuing Operations fell 7.81% to -$12.4 million in Q3 2017 from the same period last year, while for Sep 2017 it was -$65.9 million, marking a year-over-year decrease of 47.01%. This contributed to the annual value of -$57.3 million for FY2016, which is 132.00% down from last year.
- As of Q3 2017, Tvardi Therapeutics' Income from Continuing Operations stood at -$12.4 million, which was down 33.81% from -$9.3 million recorded in Q2 2017.
- Over the past 5 years, Tvardi Therapeutics' Income from Continuing Operations peaked at $5.3 million during Q2 2013, and registered a low of -$22.2 million during Q1 2017.
- Moreover, its 3-year median value for Income from Continuing Operations was -$10.7 million (2016), whereas its average is -$11.4 million.
- In the last 5 years, Tvardi Therapeutics' Income from Continuing Operations tumbled by 168.30% in 2014 and then grew by 28.87% in 2017.
- Over the past 5 years, Tvardi Therapeutics' Income from Continuing Operations (Quarterly) stood at -$2.1 million in 2013, then plummeted by 99.33% to -$4.2 million in 2014, then slumped by 128.43% to -$9.5 million in 2015, then crashed by 130.56% to -$22.0 million in 2016, then dropped by 7.81% to -$12.4 million in 2017.
- Its Income from Continuing Operations stands at -$12.4 million for Q3 2017, versus -$9.3 million for Q2 2017 and -$22.2 million for Q1 2017.